Cardiol Therapeutics (CRDL) Upgraded to ‘Strong Buy’ by Roth CapitalCardiol Therapeutics (CRDL) Upgraded to ‘Strong Buy’ by Roth Capital Roth Capital analysts have upgraded Cardiol Therapeutics (NASDAQ:CRDL) to a “strong-buy” rating in a research report issued Wednesday. Analyst Ratings and Price Targets CRDL has received positive ratings from multiple analysts: * Roth Mkm: Buy, price target €10.00 * HC Wainwright: Buy, price target $9.00 * Canaccord Genuity Group (2x): Buy, price target $8.00 * Six investment analysts: Buy (average rating) * Consensus target price: $7.60 Stock Performance NASDAQ CRDL opened at $2.05 on Wednesday, with a market cap of $141.45 million. The stock has a price-to-earnings ratio of -5.86 and a beta of 0.99. Its 12-month trading range is $0.66 to $3.12. Earnings and Financial Metrics Cardiol Therapeutics reported a loss per share of ($0.10) in its most recent quarterly earnings report, missing analysts’ estimates. Sell-side analysts forecast a loss per share of -0.33 for the current fiscal year. The company has a strong financial position with a current ratio and quick ratio of 2.81, and a debt-to-equity ratio of 0.01. Institutional Ownership Institutional investors own 12.49% of Cardiol Therapeutics’ shares. Laird Norton Trust Company LLC significantly increased its position in the company during the third quarter, acquiring an additional 38,673 shares. About Cardiol Therapeutics Cardiol Therapeutics focuses on developing anti-fibrotic and anti-inflammatory therapies for heart disease. Its lead product, CardiolRx, is in clinical trials for acute myocarditis and recurrent pericarditis.
Cardiol Therapeutics (NASDAQ:CRDL – Get a Free Report) was upgraded to a “strong-buy” rating by Roth Capital analysts in a research report issued Wednesday, Zacks.com reports.
CRDL has been the subject of a number of other reports. Roth Mkm assumed coverage of Cardiol Therapeutics shares in a research report on Wednesday. They set a buy rating and a price target of €10.00 for the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Friday, June 14. Canaccord Genuity Group raised their price target on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, May 23. Finally, Canaccord Genuity Group raised their price objective on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, May 23. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of ‘Buy’ and a consensus target price of $7.60.
View our latest report on Cardiotherapy
Cardiol Therapeutics stock performance
NASDAQ CRDL opened at $2.05 on Wednesday. The company has a market cap of $141.45 million, a price-to-earnings ratio of -5.86 and a beta of 0.99. The company has a fifty-day simple moving average of $2.19 and a 200-day simple moving average of $1.64. The company has a current ratio of 2.81, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 12-month low of $0.66 and a 12-month high of $3.12.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) ($0.04). Sell-side analysts predict that Cardiol Therapeutics will post -0.33 earnings per share for the current fiscal year.
Institutional trade in cardiol therapies
An institutional investor recently increased his position in Cardiol Therapeutics shares. Laird Norton Trust Company LLC increased its position in Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) during the third quarter up 63.1%, according to its most recent 13F filing with the SEC. The company owned 100,000 shares of the company, having acquired an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned 0.15% of Cardiol Therapeutics worth $90,000 as of the most recent SEC filing. Institutional investors own 12.49% of the company’s shares.
About Cardiol Therapeutics
(Get a free report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart disease. Its lead product, CardiolRx, is in a multinational, randomized, double-blind and placebo-controlled Phase II study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Also see
Get daily news and reviews for Cardiol Therapeutics – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Cardiol Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
